Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

被引：0
|
作者：
Mikio Sugimoto
Takuma Kato
Yoichiro Tohi
Yosuke Shimizu
Ryuji Matsumoto
Takahiro Inoue
Yutaka Takezawa
Kimihiko Masui
Hiroshi Sasaki
Hiromi Hirama
Shiro Saito
Shin Egawa
Toshiyuki Kamoto
Satoshi Teramukai
Shinsuke Kojima
Takashi Kikuchi
Yoshiyuki Kakehi
机构：
[1] Kagawa University,Department of Urology, Faculty of Medicine
[2] Kobe City Nishi-Kobe Medical Center,Department of Urology
[3] Hokkaido University Graduate School of Medicine,Department of Urology
[4] Kyoto University,Department of Urology, Graduate School of Medicine
[5] Isesaki Municipal Hospital,Department of Urology
[6] Otsu City Hospital,Department of Urology
[7] Jikei University School of Medicine,Department of Urology
[8] National Hospital Organization Tokyo Medical Center,Department of Urology
[9] University of Miyazaki,Department of Urology, Faculty of Medicine
[10] Kyoto Prefectural University of Medicine,Department of Biostatistics
[11] Foundation for Biomedical Research and Innovation at Kobe Translational Research Center for Medical Innovation,undefined
来源：
BMC Urology | / 22卷
关键词：
Combined androgen blockade; Enzalutamide; Non-metastatic castration-resistant prostate cancer; Progression-free survival; Radical treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
    Lin, Jianqing
    Elkon, Jacob
    Ricart, Brittany
    Palmer, Erica
    Zevallos-Delgado, Christian
    Noonepalle, Satish
    Burgess, Brooke
    Siegel, Robert
    Ma, Yan
    Villagra, Alejandro
    ONCOLOGIST, 2021, 26 (12) : E2136 - E2142
  • [32] Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Thomsen, Frederik Birkebaek
    Roder, Martin Andreas
    Rathenborg, Per
    Brasso, Klaus
    Borre, Michael
    Iversen, Peter
    SCANDINAVIAN JOURNAL OF UROLOGY, 2014, 48 (03) : 268 - 275
  • [33] Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
    Li, Pei-Yu
    Lu, Ying-Hao
    Chen, Chung-Yu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer
    Shore, Neal
    Antonarakis, Emmanuel
    Ross, Ashley
    Marshall, Catherine
    Stratton, Kelly
    Ayanambakkam, Adanma
    Cookson, Michael
    McKay, Rana
    Bryce, Alan
    Kaymakcalan, Marina
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 28 (2) : 250 - 259
  • [35] Prognostic factors for non-metastatic castration-resistant prostate cancer treated with androgen receptor signaling inhibitors
    Takahara, Kiyoshi
    Naiki, Taku
    Nakane, Keita
    Watanabe, Hiromitsu
    Miyake, Hideaki
    Koie, Takuya
    Yasui, Takahiro
    Shiroki, Ryoichi
    MOLECULAR AND CLINICAL ONCOLOGY, 2024, 21 (04)
  • [36] Effectiveness of Vintage Hormone Therapy as Alternative Androgen Deprivation Therapy for Non-metastatic Castration-resistant Prostate Cancer
    Iwamoto, Hiroaki
    Kano, Hiroshi
    Shimada, Takafumi
    Naito, Renato
    Makino, Tomoyuki
    Kadamoto, Suguru
    Yaegashi, Hiroshi
    Shigehara, Kazuyoshi
    Izumi, Kouji
    Kadonoa, Yoshifumi
    Mizokami, Atsushi
    IN VIVO, 2021, 35 (02): : 1247 - 1252
  • [37] Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study
    Malone, Shawn
    Wallis, Christopher J. D.
    Lee-Ying, Richard
    Basappa, Naveen S.
    Cagiannos, Ilias
    Hamilton, Robert J.
    Fernandes, Ricardo
    Ferrario, Cristiano
    Gotto, Geoffrey T.
    Morgan, Scott C.
    Morash, Christopher
    Niazi, Tamim
    Noonan, Krista L.
    Rendon, Ricardo
    Hotte, Sebastien J.
    Saad, Fred
    Zardan, Anousheh
    Osborne, Brendan
    Chan, Katherine F. Y.
    Shayegan, Bobby
    BJUI COMPASS, 2022, 3 (05): : 383 - 391
  • [38] The prognostic superiority of second-generation androgen receptor signaling inhibitor in patients with non-metastatic castration-resistant prostate cancer
    Naiki, Taku
    Takahara, Kiyoshi
    Watanabe, Hiromitsu
    Nakane, Keita
    Sugiyama, Yosuke
    Koie, Takuya
    Shiroki, Ryoichi
    Miyake, Hideaki
    Yasui, Takahiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 164 - 171
  • [39] Corticosteroids alleviate adverse events associated with enzalutamide in patients with metastatic castration-resistant prostate cancer
    Tamura, Keita
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    Miyake, Hideaki
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 12 (05) : 495 - 500
  • [40] Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
    Noonan, K. L.
    North, S.
    Bitting, R. L.
    Armstrong, A. J.
    Ellard, S. L.
    Chi, K. N.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1802 - 1807
12345